Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock
NASDAQ · LXEO
3.21
Fundamentals
Market cap
$271.71M
Price / Earnings ratio
-3.2x
Price / Sales ratio
N/A
Price / Book ratio
1.2x
Return on assets
-42.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 1 articles
published over the past 14 days
About Lexeo Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees63
CEOMr. R. Nolan Townsend M.B.A.
IPO DateNov 3, 2023
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. R. Nolan Townsend M.B.A. | CEO & Director | 1981 |
| Mr. Louis Tamayo | CFO & Principal Accounting Officer | 1977 |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — |
| Dr. Jose Manuel Otero Ph.D. | Chief Operating Officer | 1979 |
| Dr. Narinder P. Bhalla FACC, FSCAI, M.D. | Chief Medical Officer | 1964 |
| Mr. Keith Wonnacott | Senior Vice President of Regulatory Affairs | — |
| Ms. Ashley Kaplowitz | Head of Capital Markets | — |
| Mr. Ryan McHenry | VP & Corporate Controller | — |
Fundamentals
Valuation
Market cap$271.71M
Price-to-sales ratioN/A
Price-to-book value1.18
Price-earnings ratio-3.20
Return on Equity-48.00%
Return on SalesN/A
Return on Assets-42.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.02
Income Statement
Average volume998,380
EBITDA$-85.29M
1 year high (52w)$10.99
1 year low (52w)$3.33
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$15.00
Est return
342.48%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +26.6 | -12.6 | ||||||||||
| 2024 | +15.6 | -13.0 | +5.4 | -21.5 | +35.2 | -5.9 | -19.6 | -11.9 | -20.7 | -9.6 | +3.8 | -21.8 |
| 2025 | -18.6 | -48.5 | +48.3 | +25.6 | -42.3 | +47.8 | +12.1 | +3.9 | +38.6 | +50.8 | +9.1 | +11.3 |
| 2026 | -22.9 | -6.0 | -19.5 | +0.5 | -10.9 | -3.1 | -7.2 | +13.3 | -29.6 |




